• Royalty Pharma acquired part of Neurimmune’s royalty interest in AstraZeneca’s cliramitug for up to $425 million, including $125 million upfront.
• Deal grants a 3% to 4% royalty on worldwide net sales of cliramitug, a Phase 3 antibody for ATTR-CM.
• Another $125 million cash payment is due in Q1 2027; remaining $175 million tied to clinical and regulatory milestones.
• Phase 3 DepleTTR-CM trial results are expected in 2028; AstraZeneca has guided to $3 billion to $5 billion peak sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Royalty Pharma plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607220705PRIMZONEFULLFEED9766267) on July 22, 2026, and is solely responsible for the information contained therein.